60 hours mesogenic ndv is currently preferred in accordance with this invention any conventional route or technique for administering viruses to a subject can be utilized for examples of routes of administration refer to wo 00 62735 in one embodiment of this invention the virus is administered systemically for example intravenously for intravenous administration of a therapeutic virus in accordance with this invention preferably the virus is a mesogenic strain of newcastle disease virus in a preferred embodiment of this invention from 12 u00d7 10 9 to 120 u00d7 10 9 pfu m 2 per dose of a mesogenic strain of newcastle disease virus is administered intravenously to a human subject more preferably from 12 u00d7 10 9 to 48 u00d7 10 9 pfu m 2 per dose as used herein u201c mg m 2 u201d means milligrams per square meter of patient surface area in embodiments of this invention the picornavirus is a poliovirus an echovirus or a coxsackievirus examples of coxsackieviruses that are suitable in accordance with this invention include the following types a21 a13 a15 and a18 examples of suitable echoviruses include echovirus type 1 as used herein the term u201c camptothecin compound u201d means that class of compounds considered to be camptothecins camptothecin analogs camptothecin derivatives or camptothecin conjugates these compounds are based on the characteristic five ring backbone of camptothecin in accordance with this invention any camptothecin compound can be utilized examples of camptothecin compounds include irinotecan camptosar 7 ethyl 10 4 1 piperidino 1 piperidino carbonyloxycamptothecin topotecan hycamptin s 9 n n dimethylaminoethyl.